The overall goal of the AM SFC is to provide in one location the specialized facilities, equipment, and expertise to conduct research on BSL3 and Select Agent pathogens in animal models, which will promote the development of new vaccines, therapeutics, and other biodefense products for zoonotic agents. More specifically, the aims of the AM SFC are to establish and exploit for biodefense product development: 1. Facilities and expertise for aerosol inhalation studies using viral and bacterial pathogens that require high levels of containment 2. Facilities and expertise for studies involving arthropod-borne transmission using rodents as well as larger domestic animals and wildlife 3. Training to graduate and post-doctoral students, technicians and faculty members for development and implementation of animal model studies using aerosol and vector-borne transmission Personnel within the Animal Model Core will provide services to investigators at multiple levels. In some cases, personnel in the core will assist substantively in experimental design and be responsible for all aspects of animal experimentation, including delivery of the pathogen, monitoring and sampling (e.g. blood) from animals, and performing euthanasia and necropsies. This mode of service will be most applicable to investigators from other institutions and to projects involving private companies. The other end of the service spectrum will be to provide assistance as needed, especially in regard to aerosol and vector-borne delivery of pathogens. During the first year of the project, we will establish and characterize aerosol models in mice of three pathogens: the LVS strain of Francisella tularensis, LaCross encephalitis virus and rabies virus. These three pathogens are all models for important BT agents, and this work will allow personnel in the AM SFC to optimize the use of the new facility in preparation for the large number of specific projects that it will support.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI065357-03
Application #
7451028
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
3
Fiscal Year
2007
Total Cost
$365,290
Indirect Cost
Name
Colorado State University-Fort Collins
Department
Type
DUNS #
785979618
City
Fort Collins
State
CO
Country
United States
Zip Code
80523
Webb, Jessica R; Price, Erin P; Somprasong, Nawarat et al. (2018) Development and validation of a triplex quantitative real-time PCR assay to detect efflux pump-mediated antibiotic resistance in Burkholderia pseudomallei. Future Microbiol 13:1403-1418
York, Joanne; Nunberg, Jack H (2018) A Cell-Cell Fusion Assay to Assess Arenavirus Envelope Glycoprotein Membrane-Fusion Activity. Methods Mol Biol 1604:157-167
Rhodes, Katherine A; Somprasong, Nawarat; Podnecky, Nicole L et al. (2018) Molecular determinants of Burkholderia pseudomallei BpeEF-OprC efflux pump expression. Microbiology 164:1156-1167
Skyberg, Jerod A; Lacey, Carolyn A (2017) Hematopoietic MyD88 and IL-18 are essential for IFN-?-dependent restriction of type A Francisella tularensis infection. J Leukoc Biol 102:1441-1450
Plumley, Brooke A; Martin, Kevin H; Borlee, Grace I et al. (2017) Thermoregulation of Biofilm Formation in Burkholderia pseudomallei Is Disrupted by Mutation of a Putative Diguanylate Cyclase. J Bacteriol 199:
Randall, Linnell B; Georgi, Enrico; Genzel, Gelimer H et al. (2017) Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance. J Antimicrob Chemother 72:1258-1260
Podnecky, Nicole L; Rhodes, Katherine A; Mima, Takehiko et al. (2017) Mechanisms of Resistance to Folate Pathway Inhibitors in Burkholderia pseudomallei: Deviation from the Norm. MBio 8:
Cummings, Jason E; Slayden, Richard A (2017) Transient In Vivo Resistance Mechanisms of Burkholderia pseudomallei to Ceftazidime and Molecular Markers for Monitoring Treatment Response. PLoS Negl Trop Dis 11:e0005209
Pettey, W B P; Carter, M E; Toth, D J A et al. (2017) Constructing Ebola transmission chains from West Africa and estimating model parameters using internet sources. Epidemiol Infect 145:1993-2002
Furuta, Yousuke; Komeno, Takashi; Nakamura, Takaaki (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 93:449-463

Showing the most recent 10 out of 258 publications